ReviewFEMS microbiology reviews2021
The within-host evolution of antimicrobial resistance in Mycobacterium tuberculosis.
Review in FEMS microbiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 46 citations in OpenAlex.
- Can Diagnostic Delay Amplify Drug Resistance in Tuberculosis? A Critical Integrative Reflection on Bacterial Adaptation, Persistence, Within-Host Evolution, and Heteroresistance.Diseases (Basel, Switzerland) · 2026Article
- Aquaculture Pathogens and Antimicrobial Resistance: A One Health Perspective.International journal of molecular sciences · 2026Review
- Performance of next-generation sequencing technologies for detecting drug-resistant tuberculosis in people with pulmonary tuberculosis.The Cochrane database of systematic reviews · 2026Article
- Evaluating the Performance of Sputum-Based Targeted Sequencing Against Mycobacterial Whole-Genome Sequencing in Predicting Tuberculosis Drug Resistance.International journal of molecular sciences · 2026Article
- Screening for heterogeneous drug resistance in tuberculosis and its impact on clinical prognosis: A comprehensive review.iScience · 2026Review
- Heteroresistance inFrontiers in cellular and infection microbiology · 2026Review
- The eight pillars of within-host tuberculosis modelling.Frontiers in immunology · 2026Review
- Mechanisms of Antibiotic Resistance and Novel Therapeutic Approaches forHealth science reports · 2025Article
- Ecology, global diversity and evolutionary mechanisms in the Mycobacterium tuberculosis complex.Nature reviews. Microbiology · 2025Review
- Coinfection by multipleMicrobiology and molecular biology reviews : MMBR · 2025Review
- Synthesis, Antimicrobial Activities, and Model of Action of Novel Tetralone Derivatives Containing Aminoguanidinium Moiety.International journal of molecular sciences · 2025Article
- Phagosomal RNA sensing through TLR8 controls susceptibility to tuberculosis.Cell reports · 2025Article
- Genomics for antimicrobial resistance-progress and future directions.Antimicrobial agents and chemotherapy · 2025Review
- Synthesis, Antimicrobial Activities, and Model of Action of Indolyl Derivatives Containing Amino-Guanidinium Moieties.Molecules (Basel, Switzerland) · 2025Article
- Deep Amplicon Sequencing Reveals Culture-dependent Clonal Selection of Mycobacterium tuberculosis in Clinical Samples.Genomics, proteomics & bioinformatics · 2025Article
- Genomic Insights into Bacterial Antimicrobial Resistance Transmission and Mitigation Strategies.Current pharmaceutical biotechnology · 2025Review
- Review
- Traditional Herbal Plants and their Phytoconstituents Based Remedies for Respiratory Diseases: A Review.The open respiratory medicine journal · 2025Review
- Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis.PloS one · 2025Article
- Within-host population dynamics of extensively drug-resistantEvolution, medicine, and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Tuberculosis (TB) has been responsible for the greatest number of human deaths due to an infectious disease in general, and due to antimicrobial resistance (AMR) in particular. The etiological agents of human TB are a closely-related group of human-adapted bacteria that belong to the Mycobacterium tuberculosis complex (MTBC). Understanding how MTBC populations evolve within-host may allow for improved TB treatment and control strategies. In this review, we highlight recent works that have shed light on how AMR evolves in MTBC populations within individual patients. We discuss the role of heteroresistance in AMR evolution, and review the bacterial, patient and environmental factors that likely modulate the magnitude of heteroresistance within-host. We further highlight recent works on the dynamics of MTBC genetic diversity within-host, and discuss how spatial substructures in patients' lungs, spatiotemporal heterogeneity in antimicrobial concentrations and phenotypic drug tolerance likely modulates the dynamics of MTBC genetic diversity in patients during treatment. We note the general characteristics that are shared between how the MTBC and other bacterial pathogens evolve in humans, and highlight the characteristics unique to the MTBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.